Oral Insulin Delivery Strategies Using Absorption Promoters, Absorption Enhancers, and Protease Inhibitors - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Oral Insulin Delivery Strategies Using Absorption Promoters, Absorption Enhancers, and Protease Inhibitors

Pharmaceutical Technology

The early years of oral insulin research inspired pharmaceutical polymer and biomedical researchers to explore the possibility of improving the oral bioavailability of insulin and other peptide and protein drugs. A historical retrospective of oral insulin delivery methods shows that the oral absorption of both native and modified insulin in animals significantly increases with the incorporation of absorption enhancers and promoters and enzyme inhibitors, alone and in combination. Many authors have suggested that various pharmaceutical excipients in different chemical forms and concentrations could help enhance the absorption of insulin in an oral dosage form. These excipients have improved insulin absorption in laboratory animal experiments. Studies were performed to observe if any of these agents have a toxic effect on the cellular structure of the intestinal epithelium.

In vivo studies using various types of laboratory animal models have suggested that orally administered insulin is available for absorption when protected from enzymatic degradation. The experiments also were performed in vitro to observe the effect of these agents in insulin-containing formulations. Oil and water bases were prepared by using absorption enhancers and promoters. Evaluation studies on various types of enzyme inhibitors, selected based on their availability and suitability in the insulin containing formulations, also were reviewed.

Some of these studies are described in this article, with an emphasis on the delivery of oral insulin formulations containing either promoters and enhancers alone or in combination with enzyme inhibitors. This article also reviews the current state of use of absorption promoters and enhancers and enzyme inhibitors and assesses the progress and limitations of studies and reports. The article concludes with an examination of clinical outcomes of these agents characterized by increased permeability and no toxic effect.

Oral insulin delivery strategies

Enzyme-inhibiting agents. Enzyme inhibiting agents are becoming increasingly popular as a delivery strategy for oral insulin. Insulin, like many other protein and peptide drugs, may be degraded in the gastrointestinal tract (GIT) by digestive enzymes such as pepsin, proteases, peptidases, and other proteolytic enzymes. The proper selection of protease inhibitors depends on both the peptide and protein drug to be delivered and on the type of proteases and peptidases used to protect the drug in the GIT.

Table I: Select penetration and permeation enhancers and enzyme inhibitors used in various studies.
Several studies support using protease inhibitors as a protective cover to prevent the degradation of insulin by digestive enzymes, which are mostly located in the upper part of the intestine (see Table I). Investigators should conduct more in vitro experiments to evaluate the potential for cytotoxicity or other gastrointestinal side effects. Most studies cited in this article show increased permeability with little or no toxic effect.

In the 1980s, Ziv and his colleagues studied bile acid (sodium cholate) as a protease inhibitor, along with aprotinin (a trypsin inhibitor), in an insulin-containing solution. This solution was injected into rats' ileums. The results suggest that the combination of both inhibitors could improve insulin absorption in the intestinal lumen of rats (1). Interestingly, acarbose, an intestinal alpha glucosidase inhibitor, also showed some positive effects in diabetic animals (2).

A potent and specific inhibitor, 4-(4-isopropylpiper-adinocarnonyl) phenyl 1, 2, 3, 4-tetrahydro-1-naphthoate methanesulphonate (FK-448) of chymotrypsin improved intestinal absorption of insulin and resulted in a reduction in blood glucose in rats and dogs (3). Fujii's study, which used soybean trypsin inhibitors in the ileum, confirmed the earlier findings of Ziv et al. and Kidron et al. (1, 4). There is no evidence that soybean trypsin inhibitor enhanced insulin absorption in the ascending colon, however. Further attempts to increase the hypoglycemic levels in diabetic animals were made by introducing enzyme inhibitors and protease inhibitors (aprotinin or the Bowman–Birk inhibitor) to prevent the degradation of insulin in the intestine by pancreatic enzymes (5, 6).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here